GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » Net Margin %

Werewolf Therapeutics (Werewolf Therapeutics) Net Margin % : -2,182.35% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Werewolf Therapeutics's Net Income for the three months ended in Mar. 2024 was $-16.19 Mil. Werewolf Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.74 Mil. Therefore, Werewolf Therapeutics's net margin for the quarter that ended in Mar. 2024 was -2,182.35%.

The historical rank and industry rank for Werewolf Therapeutics's Net Margin % or its related term are showing as below:

HOWL' s Net Margin % Range Over the Past 10 Years
Min: -328.09   Med: -257.73   Max: -187.37
Current: -256.33


HOWL's Net Margin % is ranked worse than
56.77% of 1027 companies
in the Biotechnology industry
Industry Median: -151.78 vs HOWL: -256.33

Werewolf Therapeutics Net Margin % Historical Data

The historical data trend for Werewolf Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Werewolf Therapeutics Net Margin % Chart

Werewolf Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
- - - -328.09 -187.37

Werewolf Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -268.41 -63.09 -140.50 -799.67 -2,182.35

Competitive Comparison of Werewolf Therapeutics's Net Margin %

For the Biotechnology subindustry, Werewolf Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Werewolf Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Werewolf Therapeutics's Net Margin % falls into.



Werewolf Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Werewolf Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-37.368/19.943
=-187.37 %

Werewolf Therapeutics's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-16.193/0.742
=-2,182.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Werewolf Therapeutics  (NAS:HOWL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Werewolf Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Werewolf Therapeutics (Werewolf Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
Executives
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake officer: Chief Technology Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard officer: Chief Operating Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc 10 percent owner 800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco director 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin 10 percent owner 6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus director, 10 percent owner C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520